Gilead slides 4% after COVID-19 drug shows limited benefit in moderately ill patients

Business Insider

Published

· *Gilead's stock fell 4% on Monday after a coronavirus drug trial showed mixed results in moderately ill people. *
· *The company tested the drug in patients who received the treatment for both 5 days and 10 days. *
· *Patients who received it for 5 days were 65% more likely to show signs of recovery than those who...

Full Article